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Recombinant hirudin: A specific thrombin inhibiting anticoagulant for
hemodialysis. The first experience with hirudin as an alternative antico-
agulant for heparin in hemodialysis is reported. Recombinant hirudin
(HBW 023) was administered in 20 patients as a bolus before dialysis
with low flux polysulfone dialyzers (PS400), the dosage being adapted
stepwise from patient to patient by 0.02 mg/kg to the occurrence of
clotting or bleeding. Four different administration schedules were
studied. The first three schedules (0.02 mg/kg, N 1; 0.04 mg/kg, N =
1; 0.06 mg/kg, N = 4) were discontinued because of clotting. The 0.08
mg/kg schedule was maintained without clotting event in 14 patients.
Bleeding was not observed. Plasma hirudin averaged 503.9 214.0 and
527.7 217.1 ng/ml after two and four hours of dialysis, and decreased
during an interdialytic interval of 44 hours to 223.2 86.2 ng/ml,
Modified antithrombin III (P < 0.05) and activated partial thromboplas-
tin times were lower (P < 0.01) under hirudin compared to heparin;
these coagulation parameters were closer to normal during hirudin
treatment. The patients developing clotting could be distinguished from
those without clotting by the registration of the activated clotting times
(9.2 3.0 vs. 18.7 3.2 mm after 2 hr, P < 0.01; 8.1 3.0 vs. 16.2
3.8 mm after 4 hr of dialysis, P < 0.05); cut-off value below which
clotting is to be expected was 12 mm). It is concluded that administra-
tion of hirudin as a bolus before the start of dialysis, at a dosage of 0.08
mg/kg, is not complicated by clotting or by bleeding. Coagulation
tendency can optimally be monitored by the registration of the activated
clotting time. Residual hirudin in the blood 44 hours after the end of
dialysis will have to be taken into consideration, if this anticoagulant is
to be administered on a regular basis.
Adequate hemodialysis requires appropriate anticoagulation.
The hemo-incompatibility of the dialyzer and the dialysis circuit
may cause irreversible clotting if anticoagulation is omitted or
insufficient. Heparin is at present the most widely applied
anticoagulant for hemodialysis, but it has an incomplete anti-
coagulatory effect, which may be responsible for the deficient
resolution of clots in spite of optimal treatment, since it is well
established that fibrin bound thrombin is poorly neutralized by
ATIII-heparin complexes. In addition, several side effects with
potential implications on morbidity and mortality have been
attributed to hepann: hemorrhage, osteopenia, hyperkalemia,
thrombocytopenia, hypersensitivity reactions, hypoaldoster-
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onism, alopecia, skin necrosis, interactions with other drugs,
and hypertransaminasemia [1—4].
Subsequently, there has been a continuous search for alter-
natives. Hirudin was shown at an early stage after its detection
to be an antithrombotic agent of high quality and it was the
anticoagulant used during the first attempts to perform hemo-
dialysis [5]. At that time, the clinical use of this substance
remained limited since native hirudin was not available in
sufficient amounts for therapeutic purposes, that is, to perform
hemodialysis on a large scale. This problem could only recently
be resolved by the application of eukaryotic genetic probes to
express recombinant hirudin. Hence, thrombosis prevention
during hemodialysis was recently indicated as one of the
expected future clinical applications for the newly developed
recombinant hirudins [6].
Administration in non-uremic patients results in reliable
anticoagulation and efficient clot resolution [7—9]. Moreover,
the inhibitory effect of hirudin on clot growth has been shown to
persist even after the disappearance of the compound from the
blood [10]. Hirudin might avoid several of the problems or
complications associated with hepann use [6, 11].
Although it appears conceivable that hirudin would be appli-
cable in hemodialysis as well, feasibility studies are lacking,
except for an animal study on a limited number of dogs [12]. We
report here on the first experience with recombinant hirudin as
an anticoagulant of the hemodialysis circuit in humans, after
therapeutic safety had been documented in non-uremic healthy
volunteers in a dose-establishment study [13]. The objective of
the present study is to define the minimal effective dose. We
documented that a single bolus of 0.08 mg/kg is sufficient to
prevent clot formation in the dialysis circuit in 14 consecutive
patients, whereas no bleeding complications are registered.
Methods
Study design
The study was designed as an open, randomized, non-
comparative dose-ranging study, in successive groups. A list of
the eligible patients (not taking into account at this stage the
patient's consent) was prepared before the beginning of the
study. The order of the enrollment of these patients into the
study was then randomized.
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All patients with chronic renal failure and on regular mainte-
nance hemodialysis in the Hospital Haemodialysis Unit of the
Nephrology Department of the University Hospital Ghent were
screened for the inclusion and exclusion criteria.
Informed oral consent was obtained as approved by the
Hospital's Institutional Review Board.
Inclusion and exclusion criteria
Inclusion criteria were: age 18 to 70 years, regular mainte-
nance hemodialysis for less than three months, intra-dialysis
heparin dose 900 to 1800 IU/hr, and residual C. < 7 mI/mm.
Excluded were pregnant women, recent (< 3 weeks) surgery,
previous cerebro-vascular accident, recent (< 3 months) cranial
trauma, pleuritis requiring punctures, severe hypertension
(> 160 systolic and/or 100 mm Hg diastolic blood pressure),
endocarditis, pericarditis, cancer, hemostatic disorders favor-
ing bleeding, hepatologic disease with coagulation distur-
bances, and diabetes mellitus with proliferative retinopathy.
Equally excluded were those patients treated with vitamin K
antagonists, with platelet function inhibitors or fibrinolytic
drugs within seven days before inclusion, or with blood prod-
ucts or heparin derivatives within four days and 48 hours,
respectively, before inclusion, as well as those patients treated
with H2 antagonists.
All patients conforming with the criteria were enrolled on a
randomized list, defining the order in which they would be
entering the study, after which informed consent was obtained.
Hemodialysis strategy
Patients were treated by routine single needle hemodialysis
against bicarbonate dialysate during four hours. Dialyzer blood
flows were at 250 mI/mm and dialysate flows at 500 ml/min.
The sequence of dialyses was as follows: a control dialysis
(HD0) (regular heparin treatment at the same dosage as usual)
was followed within one week by a hirudin dialysis session
(HD1); these two dialyses were performed with a small pore
polysulfone membrane (PS400, low flux, Rapido 1.4, BL643,
Bellco, Mirandola, Italy). After this there was a wash-out
period during which hemodialysis was performed with large
pore polysulfone membranes (PS600, high flux, Rapido 1.3,
BL627, Bellco), and anticoagulation was pursued with regular
heparin administration. The rationale for the use of the high flux
dialyzers was the expected removal of hirudin through the large
pore membrane, as previously described in animal experiments
[121.
Large pore polysulfone was used for three to six consecutive
dialysis sessions. In the present study, the focus will only be on
the dialysis session during which hirudin was administered. The
remaining sessions will be considered in a separate study, in an
evaluation of the pharmacokinetics of hirudin.
Heparin and hirudin administration schemes
Heparin (Leo Pharmaceuticals, Lundbeck, Denmark) was
administered as a bolus in the arteriovenous (AV)-fistula imme-
diately before the start of dialysis at a dose of 1000 to 2000 IU,
followed by a maintenance dose ranging between 900 and 1800
lU/hr. Heparin was administered during the control dialysis
(HD0), and during the dialysis sessions of the wash-out period
(HD2 and following), always according to the same basic
administration scheme. Heparin was not administered during
the hirudin dialysis (HD1), unless an additional injection of
heparin was requested, as in the case of clotting.
Hirudin was administered as a bolus in the A-V fistula
immediately before the start of dialysis. The recombinant
hirudin used in this study (HBW 023, Hoechst AG, Frankfurt,
Germany) had structural characteristics very close to those of
natural hirudin, apart from the lack of a sulfate group on Tyr 63.
The patients were allotted to different groups based on the dose
of hirudin administered. Each group consisted of a maximum of
seven patients. A given dosage was to be discontinued in the
case of clotting or bleeding. Starting from a hirudin dose of 0.02
mg/kg, the dose was to be increased by 0.02 mg/kg at transition
to the following group in the case of clotting, or decreased by
0.02 mg/kg in the case of bleeding. In event the seven patients
completed dialysis without problems at a given dose, another
group of seven patients was to be started at the same dose,
providing clotting had been observed at a lower dose. The study
was considered as finished if two groups of seven were treated
on the same dosage without bleeding or clotting problems.
Definitions of clotting and bleeding
Clinical assessment of clotting included the registration of: (a)
clotting of the blood circuit with discontinuation of the dialysis;
(b) clotting tendency in the bubble trap chamber of the circuit
according to a 4 grade scale (0 = no clot during the entire
dialysis, 1 = increased blood viscosity, 2 = fibrin filaments, 3 =
small clots). Occurrence of major clotting (defined as criteria a
plus b,3) in one patient was sufficient to discontinue a given
dosage scheme.
Clinical bleeding events were defined as major: (a) if they
produced a fall in hemoglobin by > 3 g/dl; (b) if they were
located retroperitoneally or intracranially; or (c) if bleeding of
the fistula was thus that the compression time of the A-V fistula
was increased by > 50%, as compared to the value obtained
with regular heparin anticoagulation. Otherwise bleeding events
were considered as minor.
Follow-up parameters
Markers reflecting activation of coagulation. Blood sam-
pling. Blood was sampled by puncture of the inlet blood line of
the hemodialysis circuit at different time points, as illustrated in
Table 1. After discarding of 2 ml, blood for measurement of
fibrinopeptide A (fpA) and of prothrombin fragments Fl +2 was
collected on a special anticoagulant [consisting of citrate (0.11
M), heparin (1,000 IU/ml), aprotinin (1 TIU/ml), and sodium
azide as a preservative, 9 vol/i vol] (Diagnostica Stago,
Asnières-sur-Seine, France). Blood for the measurement of
modified antithrombin III (ATm), activated partial thrombo-
plastin time (aPTT), D-dimers, fibrin monomers and thrombin-
hirudin (Fila-hirudin) complexes was collected on citrate 3.8%
(9 vol/l vol). Centrifugation was performed within 10 minutes
after sampling and plasma was collected and frozen at —80°C,
except for the samples for determination of aPTT that were
collected in separate tubes and processed immediately.
Blood for determination of platelet counts was collected on
EDTA.
For the determination of activated clotting time (ACT), two
ml of blood were collected in Hemacron CA 510 tubes (Inter-
national Technidyne Corporation, Edison, New Jersey, USA),
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A modified
to be processed immediately after gentle stirring to suspend the
activator.
Blood for the measurement of anti-hirudin and anti-yeast
antibodies was collected on dry tubes.
Measurement of markers. (1) Fibrinopeptide A. Plasma was
treated twice with bentonite (27 mg/ml) and fpA was measured
by an immuno-enzymologic assay using Asserachrom fpA
(Diagnostica Stago).
(2) Modjfied antithrombin III. ATm was measured using
Asserachrom ATm. It consists of a "sandwich" ELISA using
immobilized monoclonal F'(ab')2 fragments directed against
ATm as capture antibody and a peroxidase labeled polyclonal
immunoglobulin against AT as Tag antibody (Diagnostica
Stago).
(3) Prothrombin fragments Fl +2. Prothrombin fragments
Fl +2 were measured by a two stage ELISA, using a solid phase
anti-Fl +2 monoclonal antibody and a rabbit polyclonal anti-
body coupled with peroxidase (Organon Teknica Corporation,
Durham, North Carolina, USA).
(4) D-dimers. D-dimers were measured by ELISA using D-DI
Asserachrom (qualitative and semi-quantitative determination)
(Diagnostica Stago).
(5) Fibrin monomers. Fibrin monomers were evaluated by
measurement of the increase in D-dimers after addition of tissue
plasminogen activator (tPA) to plasma, as previously described
[14].
(6) Thrombin-hirudin complexes. Flia-hirudin complexes
were measured by a "sandwich" ELISA, based upon the
capture of the complex using immobilized Ig anti-human throm-
bin antibody and detection using a peroxidase labeled rabbit
polyclonal anti-hirudin antibody (Ig anti-thrombin and peroxi-
dase labeled anti-hirudin provided by J Amiral, Serbio Labora-
tory, Jennevilliers, France).
(7) Activated partial thromboplastin time. APTT was mea-
sured on fresh plasma using aPTT silica (Instrumentation Lab-
oratory, Milan, Italy), in a modification of previously described
methodology [15].(8) Platelet counts. Platelet counts were determined by
Coulter Counter.
Hirudin (HBW 023) plasma level. This assay is based on the
property of thrombin to hydrolyze a chromogenic substrate, as
previously described [16].
In brief, citrated plasma samples were treated with acid, heat
(to denaturate fibnnogen and antithrombin III), and protamine
(6.3 jsg/ml) in order to neutralize heparin that was possibly
present [17]. Hirudin containing samples were incubated with
thrombin. The remaining thrombin activity was then measured
using a synthetic chromogenic substrate.
Antibody determination. Anti-hirudin and anti-yeast antibod-
ies were determined on serum by ELISA, using an anti-IgG
antibody. The test for anti-yeast antibodies was included for
safety reasons, because HBW 023 is obtained from yeast.
Activated clotting time (ACT). The Hemochron tube was
introduced into a Hemochron 400 appliance (International
Technidyne Corporation). The ACT (sec) was read from the
screen and converted (in mm) according to the manufacturer's
instructions.
Clinical parameters. Data concerning the evolution of body
weight, blood pressure, pulse, temperature and general condi-
tion were collected every hour during each dialysis.
Statistical analyses
All data are expressed as means standard deviation (±sD).
For ACT and fpA, the ranges of possible values were 5 to 24
minutes and 3 to 50 ng/ml, respectively. Values out of this range
were considered equal to the corresponding lower or upper
limits. Comparisons between data obtained in the same patients
at different moments of the study were compared by a paired
Wilcoxon's test (rank test). The remaining comparisons (for
example, between patients with and without clotting events)
were performed by the unpaired Wilcoxon's test or by the
unpaired Student's t-test where appropriate. Significance was
accepted for P <0.05.
Results
A total of 20 patients (9 males, 11 females, age 44 to 69 years)
were enrolled, In the HD0 (with hepann anticoagulation),
heparin was administered according to the usual dosage sched-
ule as an initial bolus (mean 1500.0 607.0 IU), followed by a
maintenance dose (1485.0 370.3 IU/hr) (total administered
dose per session 3500 to 9200 IU, that is, 7077.5 2273.3 IU).
Dose definition studies
The patients were enrolled to the different dose groups as
described in the Methods section. Stratum 1 and 2(0.02 and 0.04
mg/kg) both consisted of only one patient, as clotting was
observed in the dialyzer circuit respectively in the middle and at
the end of HD1. The patient in stratum 1 needed an extra dose
of heparin. Stratum 3 (0.06 mg/kg) consisted of four patients,
because clotting was observed at the end of dialysis in the
fourth patient. Stratum 4 (at 0.08 mg/kg) consisted of two
groups of seven patients where no clots were observed. No
bleeding events were registered in all 20 patients.
Biochemical parameters
Hirudin treatment. Hirudin plasma levels rose from 0 before
the start of the hirudin dialysis (HD1T0) to 503.9 214.0 (range
304 to 1222) at two hours (HDJT2) and to 527.7 217.1 (range
327 to 1235 ng/ml) at the end of dialysis (HD1T4) (Fig. 1). At the
Table 1. Biochemical parameters under evaluation
a Additional biological data are: fibrinopeptide (fpA);
antithrombin III (ATm); prothrombin fragments Fl ÷2; D-dimers; fibrin
monomers; thrombin (Ella) hirudin complexes.
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Fig. 1. Plasma hirudin levels during hirudin dialysis (ND1), and at the
start of the first of the wash-out dialyses (HD2) in all patients under
study (N = 20). The time points at 0, 2 and 4 hours refer to the
beginning, middle and end of HD1. The time point 48 hours refers to the
beginning of HD2.
beginning of HD2, this value had declined to 223.2 86.2 (range
87 to 364 ng!ml; P <0.001 vs. HDIT2 and HDIT4).
Although the hirudin plasma levels were lower in the three
patients showing clots, the differences were not significant (P =
0.09 at HD1T4; Table 2).
ACT was markedly lower in those patients showing clotting
(Table 2). The ACT at the moment of clotting was 7.0, 10.2 and
6.0 minutes, respectively, well below the mean values obtained
in those patients showing no clots (18.7 3.2 and 16.2 3.8
mm, respectively, after 2 hr and at the end of dialysis; range
14.1 to >24.0 and 8.5 to >24.0 mm). There were no differences
in aPTT between patients with and without clots (Table 2).
Also, for the remaining coagulation parameters (fpA, ATm,
prothrombin fragments Fl +2, D-dimers, fibrin monomers and
Fila-hirudin complexes), there were no differences between
patients with and without clotting (data not shown).
Hirudin vs. heparin. When comparing the coagulation param-
eters during dialysis with heparin (HD0) versus dialysis with
hirudin (HD1) (considering only the patients without clotting),
the value of ACT (16.4 3.7 vs. 19.7 5.2 mm at T4, %
difference = —20.0%, P 0.059) and of aPTT (65.0 11.1 vs.
123.6 48.9 sec at T4, % difference = —47.4%, P < 0.01) were
lower during hirudin treatment (Fig. 2). FpA remained slightly
higher (8.5 5.2 vs. 4.9 1.6 ng/ml at T4, P < 0.05), whereas
ATm was lower at T2 (47.8 21.9 vs. 71.9 52.5 ng/ml, P <
0.05). Finally, prothrombin fragments Fl +2 were higher during
hirudin anticoagulation (P < 0.05 at T4) (Fig. 2). No differences
were observed for the other coagulation parameters. Note that
the change versus pre-dialysis was less marked during treat-
ment by hirudin, compared to heparin, for fpA, ACT, aPTT as
well as ATm.
The plasma levels of FIla-hirudin complexes during the
hirudin hemodialysis (HD1) amounted to 8.9 2.4 at T2 and
11.0 2.7 units at T4.
ACT, aPTT and thrombocyte counts collected at the begin-
ning of HD0, HD1 and HD2 are compared to each other in Table
3. The values of ACT and aPTT were higher at HD2TO (dialysis
following the hirudin administration) compared to the two other
dialyses (P < 0.001), because of the residual hirudin.
Before
dialysis
(HDITO)
2 Hours of
dialysis
(HD1T2)
End of
dialysis
(HD1T4)
Hirudin plasma
levels ng/m!
No clots 0 531.4 207.5 559.9 206.2
Clots 0 348.7 219.4 344.7 220.0
Activated clotting
time mm
No clots 6.2 1.8 18.7 3.2 16.2 3.8
Clots 5.7 2.1 9.2 30b 8.1 3.0
Activated partial
thromboplastin
time sec
No clots 31.3 4.6 70.5 22.7 63.2 10.9
Clots 32.1 2.8 97.6 63.1 57.8 9.8
Fibrinopeptide A
ng/ml
No clots 39.9 18.3 12.8 12.7 8.6 5.0
Clots 20.0 15.1 10.7 6.8 9.3 5.5
Development of antibodies. No development of antibodies
against hirudin or yeast were registered.
Clinical parameters
No differences in clinical parameters were observed apart
from a slightly higher systolic blood pressure during hirudin
after one hour of dialysis (heparin 132 23, hirudin 137 23
mm Hg, P < 0.05). No significant differences were observed at
the other time points. Compression time of the fistula was
identical after HD0 and HD1 (11.0 2.1 vs. 11.5 2.8 mm).
Discussion
The achievability of anticoagulation by recombinant hirudin
was evaluated and proven in hemodialyzed patients. A bolus
administration of 0.08 mg/kg at the start of dialysis prevented
blood clotting during the entire dialysis session in 14 consecu-
tive patients. In those 14 patients, as well as in six patients
treated at lower doses, no bleeding complications were regis-
tered.
Hirudin is a 65 amino acid polypeptide (molecular wt 7,000
Da), acting as a thrombin-specific inhibitor, whereby the active
center of thrombin is blocked after the formation of tight
stoichiometric complexes [18]. It is presently the most potent
known natural inhibitor of thrombin [11].
All patients developing clotting under hirudin have an acti-
vated clotting time (ACT) well below the values obtained in
non-clotting patients (Table 2). According to the present data,
values lower than 12 minutes tend to be predictive for the
development of clotting, and should lead to the administration
of an additive dose.
According to our data, hirudin remains accumulated in de-
tectable levels in the blood of patients with end-stage renal
disease for a period of at least 48 hours after its administration.
This is essentially attributed to the loss of renal function,
interfering with the normal elimination of the compound in
800
600
400
200I
Table 2. Parameters of coagulation during the hirudin dialysis
session (HD1)
No clots: N = 17; clots: N = 3.
a P < 0.05, b P < 0.01 vs. no clots
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Fig. 2. Evolution of different coagulation
parameters during HD0 (heparin, —) and HD1(hirudin, — — —). = 0.059; ** < 0.05; ***
<0.01). The values obtained remain in
general closer to the pre.dialysis parameters
for hirudin than for heparin, except for
prothrombin fragments Fl +2.
Table 3. Evolution of ACT, aPTT and platelet count at the beginning
of the three dialyses
HD0TO HD1T0 HD2TO
ACT mm 7.3 2.5 6.2 1.8 13.6 4•3ab
aNT sec 30.8 5.6 31.3 4.6 56.4 l2.5'
Platelet count 269 96 270 87
X 1O3/mm
Abbreviations are: ACT, activated clotting time;
partial thromboplastin time.
a P < 0.001 vs. HDOTO
b P < 0.001 vs. HDIT0
aPTT, activated
unaltered state in the urine [19]. This residual hirudin will have
to be taken into account for the subsequent doses of heparin to
be administered, if therapeutic use in hemodialysis patients on
a regular basis is considered. However, the maximal value
registered at the beginning of the dialysis following the hirudin
treatment (HD2) (364 nglml for a mean of 223.2 86.2; Fig. 1)
is well below the maximal value registered in our patients
during the course of HD1 (1235 nglml), and 2.5 times lower than
the Cmax obtained in healthy volunteers (996 ng/mI), whereby
each time no bleeding tendencies were observed [13].
Nevertheless, it should be stressed that this residual hirudin
will have to be taken into account for the subsequent doses of
hirudin to be administered, if its therapeutic use in hemodialysis
patients on a regular basis is considered. Especially with a
dialysis frequency of two to three times per week, the likelihood
of accumulation of hirudin activity is substantial, and may
become a potential cause of safety problems.
The bleeding risk with unfractionated heparin, as it is used
today for routine dialysis, is considered low in the absence of
other pathologic events enhancing bleeding tendency. The
bleeding risk with the recently propagated low molecular weight
heparins may be even lower than with conventional heparin [4]
However, among the side effects of heparin, hemorrhage re-
mains the primary one [20]. Heparin has a direct effect on
platelets, endothelial cells, and several activated coagulation
factors (factors ha, IXa, Xa, XIa, XIIa) [21], enhancing the
associated risk of bleeding. No bleeding event has been re-
ported with the hirudin treatment regimen proposed here.
These results, observed in a small series of patients who had no
other cause for bleeding, need to be confirmed.
It is of note that changes of coagulation tests versus pre-
dialysis were in general less pronounced during treatment with
hirudin compared with heparin (Fig. 2). However, differences
were rather subtle, whereas the blood under evaluation was
potentially subject to a substantial degree of in Vitro activation,
in spite of the addition of inhibitors, so that the latter data
should be considered with the necessary care.
These differences were the least pronounced for fpA. How-
ever, in view of the low molecular weight of fpA (± 1,600
Daltons), it is a conceivably poor marker of activation of
coagulation during hemodialysis; considering the cut-off of the
dialyzer membranes used, it crosses the membrane during
dialysis and is cleared from the plasma. This may also explain
why no differences were observed in fpA between patients
presenting with and without clots.
A different evolution compared to most other coagulation
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parameters (fpA, ACT, aPTT, ATm) was observed for pro-
thrombin fragments P1+2, which showed a higher rise versus
pre-dialysis in the patients under hirudin treatment than in those
under heparin. This can be attributed to the fact that heparin-
antithrombin III complex blocks all serine proteases implicated
in thrombin generation (factors Xa, XIa, XIIa). In contrast,
hirudin is a selective thrombin inhibitor that does not block the
factors involved in thrombin generation: if thrombin is gener-
ated, this results in an increase of fragment Fl +2. The gener-
ated thrombin remains, however, inactive due to its neutraliza-
tion by hirudin, as shown by the presence of thrombin-hirudin
complexes and the slight increase in ATm compared with the
other markers of coagulation activation.
Modified antithrombin III (antithrombin modified by active
thrombin) may be considered in these patients as a good marker
of thrombin activity. ATm levels were significantly higher
during heparin dialysis (Fig. 2). The markedly less pronounced
increase in ATm in the patients under hirudin therapy suggests
the efficiency of hirudin to avoid coagulation during dialysis, or
else that low-grade intrinsic fibrin deposition is not as inhibited
with hirudin at the dose used in this study as with heparin at the
dose used in this study.
One point of concern might be the development of hirudin
antibodies, as reported by Spinner, StOffier and Fink in sheep
[22]. According to our data, no antibodies developed in hirudin
treated men, even after a delay of three weeks.
There are a number of differences in the way anticoagulation
is induced by hirudin and heparin. Unlike heparin, hirudin is a
specific inhibitor of thrombin not inactivated by anti-heparins
such as platelet factor 4 (PF4), histidine-rich glycoprotein, and
vibronectin, whereas it does not require the natural anticoagu-
lant, antithrombin III, as a cofactor [6]. For a given prolonga-
tion of aPTT, hirudin may have a different effect in inhibiting
thrombin bound to fibrin and/or vascular endothelium [23], and
in preventing thrombus formation and growth, even after a
short treatment course [24], compared to heparin. Moreover,
the antithrombotic effect of hirudin lasts at least eight hours
after aPTT has returned to normal [10]. The development of
clots and/or thromboses in the vascular access systems (A-V
fistulas or central catheters) remains among the major problems
affecting the efficacy of dialysis treatment [25, 26].
It therefore seems worthwhile in the future to evaluate
whether systematic, routine hirudin anticoagulation would de-
crease the incidence and/or the severity of these alterations.
Nevertheless, the present data should be considered with the
necessary care. In view of the accumulation of hirudin, it is
possible that hirudin will be not much safer than unfractionated
heparin, unless an antidote is developed.
Reprint requests to Raymond Vanholder, M.D., Nephroiogy Depart-
ment, University Hospital, De Pintelaan 185, B9000 Ghent, Belgium.
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